MedWatch

Analyst predicts more monkeypox orders as Bavarian Nordic enjoys trading surge

Though monkeypox cases are on the decline, nations the world over have looked to Bavarian Nordic to build vaccine stockpiles for the future – which makes for a good financial foundation for the firm, says a Sydbank analyst.

Photo: Bavarian Nordic / PR

Søren Løntoft Hansen, senior equity analyst at Danish bank Sydbank, believes that Bavarian Nordic will make more deals for its monkeypox/smallpox vaccine with nation states in coming years, as he comments on Tuesday’s news that the Danish drugmaker has signed a new million-dollar supply agreement with Canada.

In a press release, the company announced that an existing deal with Public Health Agency of Canada, PHAC, had been revised. Combining the old and new contracts worth USD 56m and USD 234m, respectively, alongside contract options valued at USD 180m, the new Canadian deal runs up to a total of USD 470m.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs